Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

T-Cell Redirecting Bispecific Antibodies Report 2016 - Analysis, Technologies & Forecasts - Key Vendors: Adimab, Affimed Therapeutics, Alligator Biosciences - Research and Markets

Research and Markets
Posted on: 01 Sep 16

Research and Markets has announced the addition of the "T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals" report to their offering.

Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields of cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell receptors (TCR).

Despite stunning clinical results with CD19-targeted CAR T-cells, many major pharmaceutical companies have not embarked on this field of adoptive cell therapy, probably because cell products are a world completely different from that of small molecules or recombinant proteins and antibodies.

Tremendous progress in bispecific antibody technologies during the last decade and the clinical success of a first generation bispecific T-cell engager (BiTE) antibody molecule directed against CD19 lead to an explosion of T-cell redirecting bispecific antibodies in clinical development.

What will you find in the report?

  • Profiles of 34 companies active in the field
  • Comprehensive description of 23 established and emerging T-cell or NK-cell redirecting antibodies
  • Profiles of two approved and 45 T-cell or NK-cell redirecting bispecific antibodies in all phases of development
  • Key characteristics of technologies with clinical stage drug candidates
  • Emerging alternative bi- and trispecific formats
  • Target selection and competition in drug candidates
  • Competition of recombinant bispecific molecules with alternative treatment modalities

Companies Mentioned Include:

  • Adimab
  • Affimed Therapeutics
  • Alligator Biosciences
  • Ambrx
  • Amgen
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • CytomX
  • Eli Lilly
  • Emergent BioSolutions
  • EngMab
  • Eureka Therapeutics
  • GEMoaB
  • Generon
  • Genmab
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Pfizer
  • Pieris Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Roche
  • Servier
  • Wuhan YZY Biopharma
  • Xencor
  • Zymeworks

Report Structure:

1. Introduction

2. Executive Summary

3. Competitive Landscape Analysis

4. Company Profiles

5. Technology Profiles

6. Drug & Drug Candidate Profiles

7. References

8. Attachment

For more information about this report visit http://www.researchandmarkets.com/research/ckb55n/tcell

View source version on businesswire.com: http://www.businesswire.com/news/home/20160901005592/en/

Business Wire
www.businesswire.com

Last updated on: 01/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.